Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Mirati Therapeutics Inc's Business Segments
Mirati Therapeutics Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
-
Largest Segment
-
Total Revenue
$ 16
Regions Reported
-
Mirati Therapeutics Inc does not report a distinct business-segment axis in its filings - its disaggregated revenue is disclosed by product and service category instead. See the Product & Service breakdown below.
Revenue by Product & Service Category - FY
- Product Revenue100%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Product Revenue | $ 16 | 100% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of Mirati Therapeutics Inc
Mirati Therapeutics Inc. is a biotechnology company specializing in the discovery and development of targeted oncology therapeutics. The company focuses on developing innovative treatments for patients with cancer by leveraging its expertise in small molecule drug discovery and deep understanding of cancer biology.
Mirati Therapeutics was founded in 1995 and is headquartered in San Diego, California. The company has a strong commitment to advancing precision medicine and improving patient outcomes through the development of personalized therapeutics. Mirati's ultimate goal is to develop novel treatments that specifically target genetic and epigenetic drivers of cancer, thereby providing patients with more effective and lasting responses.
Mirati's research and development efforts are primarily focused on developing targeted therapies for patients with solid tumors. The company's lead pipeline candidate is adagrasib, a potent and selective small molecule inhibitor of KRAS G12C, which is a common oncogenic mutation found in various types of cancer, including non-small cell lung cancer (NSCLC), colorectal cancer, and pancreatic cancer. Adagrasib has shown promising results in early clinical trials and is currently being evaluated in multiple ongoing studies.
In addition to adagrasib, Mirati has a robust pipeline of other targeted therapies in various stages of development. For example, MRTX849 is a selective small molecule inhibitor of KRAS G12C, similar to adagrasib, but with a distinct binding mechanism. MRTX849 is being developed for patients with advanced solid tumors harboring the KRAS G12C mutation.
Mirati's development strategy revolves around identifying cancer drivers, understanding their molecular characteristics, and designing targeted therapies to inhibit or modulate them. The company utilizes advanced genomic profiling techniques to identify specific genetic alterations in tumor samples and develop therapies against these targets. This precision medicine approach allows for the development of therapies that are tailored to each patient's unique molecular profile.
Mirati Therapeutics collaborates with leading academic institutions, research organizations, and pharmaceutical companies to strengthen its drug development pipeline and accelerate the pace of innovation. The company has established partnerships with top-tier institutions like Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, and Novartis Pharmaceuticals.
In summary, Mirati Therapeutics Inc. is a biotechnology company focused on developing targeted oncology therapeutics for patients with solid tumors. The company's research and development efforts are centered around identifying and targeting specific genetic alterations that drive cancer growth. Through its innovative approach, Mirati aims to provide personalized treatments that improve patient outcomes and revolutionize cancer care.
Mirati Therapeutics was founded in 1995 and is headquartered in San Diego, California. The company has a strong commitment to advancing precision medicine and improving patient outcomes through the development of personalized therapeutics. Mirati's ultimate goal is to develop novel treatments that specifically target genetic and epigenetic drivers of cancer, thereby providing patients with more effective and lasting responses.
Mirati's research and development efforts are primarily focused on developing targeted therapies for patients with solid tumors. The company's lead pipeline candidate is adagrasib, a potent and selective small molecule inhibitor of KRAS G12C, which is a common oncogenic mutation found in various types of cancer, including non-small cell lung cancer (NSCLC), colorectal cancer, and pancreatic cancer. Adagrasib has shown promising results in early clinical trials and is currently being evaluated in multiple ongoing studies.
In addition to adagrasib, Mirati has a robust pipeline of other targeted therapies in various stages of development. For example, MRTX849 is a selective small molecule inhibitor of KRAS G12C, similar to adagrasib, but with a distinct binding mechanism. MRTX849 is being developed for patients with advanced solid tumors harboring the KRAS G12C mutation.
Mirati's development strategy revolves around identifying cancer drivers, understanding their molecular characteristics, and designing targeted therapies to inhibit or modulate them. The company utilizes advanced genomic profiling techniques to identify specific genetic alterations in tumor samples and develop therapies against these targets. This precision medicine approach allows for the development of therapies that are tailored to each patient's unique molecular profile.
Mirati Therapeutics collaborates with leading academic institutions, research organizations, and pharmaceutical companies to strengthen its drug development pipeline and accelerate the pace of innovation. The company has established partnerships with top-tier institutions like Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, and Novartis Pharmaceuticals.
In summary, Mirati Therapeutics Inc. is a biotechnology company focused on developing targeted oncology therapeutics for patients with solid tumors. The company's research and development efforts are centered around identifying and targeting specific genetic alterations that drive cancer growth. Through its innovative approach, Mirati aims to provide personalized treatments that improve patient outcomes and revolutionize cancer care.
Mirati Therapeutics Inc. a biotechnology company based in the United States, primarily focuses on identifying, developing, and commercializing innovative therapies for the treatment of genetically defined cancers. Their portfolio is particularly centered on targeted therapies that address specific genetic mutations and alterations. Below are the key segments, products, and services offered by Mirati Therapeutics:
1. Oncology Pipeline
Mirati Therapeutics has built a robust oncology pipeline targeting specific genetic targets associated with cancer. The drugs are designed to exploit the unique genetic or molecular features of tumors, leading to more effective treatment with potentially fewer side effects.
A. Targeted Therapies
- Mutant KRAS Inhibitors:
- Krazati (adagrasib): This is one of the prominent products from Mirati, specifically targeting the KRAS G12C mutation. It is designed to inhibit the mutated KRAS protein found in various cancers, such as lung and colorectal cancer. The efficacy of adagrasib is being evaluated in several clinical trials across various types of solid tumors.
- Other Genetic Targets:
- Mirati is involved in developing therapies that also address other mutations, including those related to EGFR, p53, and various other oncoproteins that play crucial roles in tumor growth and survival.
B. Combination Therapies
- Mirati explores combination treatments to enhance efficacy and overcome resistance in cancer therapies. This includes pairing its targeted therapies with immunotherapies or chemotherapy, aiming to provide a multi-faceted approach to treatment.
Research and Development
A. Early-Stage Programs
- In addition to its marketed products, Mirati is involved in research for novel agents that target alternate pathways and mutations, focusing on precision medicine. The companys R&D efforts are aimed at identifying new molecular targets and developing therapies to address unmet needs in oncology.
B. Clinical Trials
- A significant part of Miratis operations involves conducting clinical trials to evaluate new therapies. The company actively participates in Phase 1, 2, and 3 trials to establish the safety, tolerability, and efficacy of its novel drug candidates.
Collaborations and Partnerships
Mirati Therapeutics often collaborates with other biotech firms, pharmaceutical companies, and academic institutions to enhance its research capabilities and expand its clinical pipeline. These partnerships may focus on co-developing drug candidates targeting shared interests in oncology.
Regulatory Affairs and Compliance
As a biotech company involved in developing and marketing therapeutic agents, Mirati complies with extensive regulatory standards. This includes engaging with agencies such as the FDA in the United States to ensure its products meet safety and efficacy guidelines.
Commercialization and Market Access
Once a drug receives regulatory approval, Mirati engages in activities related to commercialization. This includes:
- Market Analysis: Understanding market dynamics and identifying target populations for its therapies.
- Sales and Marketing: Developing strategies to position its products in the market effectively.
- Patient Access Opportunities: Creating programs to ensure patients can access their therapies, including financial assistance and education initiatives.
Patient and Healthcare Provider Engagement
Mirati emphasizes education and support for both patients and healthcare providers. This includes:
- Educational Programs: Providing information about its products, treatment options for genetically defined cancers, and clinical trial opportunities.
- Patient Support Services: Offering resources that help patients navigate their treatment journey, manage side effects, and understand the importance of genetic testing in tailored therapies.
Conclusion
Mirati Therapeutics Inc. is a key player in the biotechnology sector with a robust focus on developing targeted therapies for genetically defined cancers. Its commitment to innovation through research and development underpins its efforts to bring new, effective cancer treatments to market, ultimately aiming to improve patient outcomes across various oncology indications. The companys dynamic approach, involving collaboration and patient engagement, positions it strongly within the field of precision medicine.
1. Oncology Pipeline
Mirati Therapeutics has built a robust oncology pipeline targeting specific genetic targets associated with cancer. The drugs are designed to exploit the unique genetic or molecular features of tumors, leading to more effective treatment with potentially fewer side effects.
A. Targeted Therapies
- Mutant KRAS Inhibitors:
- Krazati (adagrasib): This is one of the prominent products from Mirati, specifically targeting the KRAS G12C mutation. It is designed to inhibit the mutated KRAS protein found in various cancers, such as lung and colorectal cancer. The efficacy of adagrasib is being evaluated in several clinical trials across various types of solid tumors.
- Other Genetic Targets:
- Mirati is involved in developing therapies that also address other mutations, including those related to EGFR, p53, and various other oncoproteins that play crucial roles in tumor growth and survival.
B. Combination Therapies
- Mirati explores combination treatments to enhance efficacy and overcome resistance in cancer therapies. This includes pairing its targeted therapies with immunotherapies or chemotherapy, aiming to provide a multi-faceted approach to treatment.
Research and Development
A. Early-Stage Programs
- In addition to its marketed products, Mirati is involved in research for novel agents that target alternate pathways and mutations, focusing on precision medicine. The companys R&D efforts are aimed at identifying new molecular targets and developing therapies to address unmet needs in oncology.
B. Clinical Trials
- A significant part of Miratis operations involves conducting clinical trials to evaluate new therapies. The company actively participates in Phase 1, 2, and 3 trials to establish the safety, tolerability, and efficacy of its novel drug candidates.
Collaborations and Partnerships
Mirati Therapeutics often collaborates with other biotech firms, pharmaceutical companies, and academic institutions to enhance its research capabilities and expand its clinical pipeline. These partnerships may focus on co-developing drug candidates targeting shared interests in oncology.
Regulatory Affairs and Compliance
As a biotech company involved in developing and marketing therapeutic agents, Mirati complies with extensive regulatory standards. This includes engaging with agencies such as the FDA in the United States to ensure its products meet safety and efficacy guidelines.
Commercialization and Market Access
Once a drug receives regulatory approval, Mirati engages in activities related to commercialization. This includes:
- Market Analysis: Understanding market dynamics and identifying target populations for its therapies.
- Sales and Marketing: Developing strategies to position its products in the market effectively.
- Patient Access Opportunities: Creating programs to ensure patients can access their therapies, including financial assistance and education initiatives.
Patient and Healthcare Provider Engagement
Mirati emphasizes education and support for both patients and healthcare providers. This includes:
- Educational Programs: Providing information about its products, treatment options for genetically defined cancers, and clinical trial opportunities.
- Patient Support Services: Offering resources that help patients navigate their treatment journey, manage side effects, and understand the importance of genetic testing in tailored therapies.
Conclusion
Mirati Therapeutics Inc. is a key player in the biotechnology sector with a robust focus on developing targeted therapies for genetically defined cancers. Its commitment to innovation through research and development underpins its efforts to bring new, effective cancer treatments to market, ultimately aiming to improve patient outcomes across various oncology indications. The companys dynamic approach, involving collaboration and patient engagement, positions it strongly within the field of precision medicine.